Eating disorders: bulimia nervosa (BN) and binge eating disorder (BED) Mental and Behavioural Disorders
Conditions
Interventions
This study focuses on two eating disorders: bulimia nervosa (BN) and binge eating disorder (BED). Both conditions involve recurrent episodes of binge eating, with BN also characterised by compensatory
Sponsors
University College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Individuals who seek treatment for bulimia nervosa (BN) and binge eating disorder (BED) according to DSM-5 (American Psychiatric Association, 2013) 2. Individuals aged 18–60 years who have a BMI of 18.5 or more 3. Literate in reading and writing 4. Need to have access to a computer, tablet, or cell phone (with a camera and microphone) and high-speed internet
Exclusion criteria
Exclusion criteria: 1. Individuals with a BMI less than 18.5 2. Pregnant women and individuals with substance dependence 3. Patients with major psychiatric disorders or acutely suicidal tendencies, patients who are receiving any kind of psychotherapy specifically for BED and BN 4. Existence of a current major medical illness that would interfere with treatment (e.g., cancer or diabetes or hypothyroidism 5. Patients on antidepressant medication or sleep medication who have not been on a stable dose for at least 4 months 6. Individuals follow any diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following primary outcome measures are assessed at at baseline, week 12 (post-treatment), and 3-month follow-up: 1. Eating disorder symptoms are measured using the Eating Disorder Examination Questionnaire (EDE-Q) 2. Binge eating severity is measured using the Binge Eating Scale (BES) 3. Emotion regulation difficulties are measured using the Difficulties in Emotion Regulation Scale (DERS) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Self-esteem is measured using the Rosenberg Self-Esteem Scale (RSES) at baseline, week 12, and 3-month follow-up 2. Anxiety symptoms are measured using the Generalised Anxiety Disorder-7 (GAD-7) at baseline, week 12, and 3-month follow-up 3. Depressive symptoms are measured using the Patient Health Questionnaire-9 (PHQ-9) at baseline, week 12, and 3-month follow-up 4. Overall quality of life is measured using the World Health Organization Quality of Life questionnaire (WHOQOL-BREF) at baseline, week 12, and 3-month follow-up 5. Life satisfaction is measured using the Satisfaction With Life Scale (SWLS) at baseline, week 12, and 3-month follow-up 6. Treatment satisfaction is measured using the Client Satisfaction Questionnaire (CSQ-I) at week 12 7. Treatment adherence is measured through participant engagement in weekly skill practice, completion of DBT worksheets, and participation across the 12-week intervention period. Adherence will be monitored through module completion, login frequency (where applicable), frequency of communication with the therapist via secure social messaging platforms, and consistency in practising assigned DBT skills. 8. Perceived acceptability and appropriateness of the intervention are measured using the Attitudes Toward Psychological Online Interventions (APOI) at baseline, and week 12 | — |
Countries
Iran
Contacts
Public ContactBahareh;Amy Dastan;Harrison
;
Outcome results
None listed